Navigation Links
Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
Date:8/5/2009

RALEIGH, N.C., Aug. 5 /PRNewswire/ -- Cancer Centers of North Carolina, an affiliate of US Oncology, Inc., continues to offer cutting-edge treatment options to its patients through the addition of High Dose Rate (HDR) brachytherapy. This latest advance in brachytherapy allows physicians to deliver precise radiation treatment to a patient's cancerous tumor and is rapidly becoming the treatment of choice for certain types of cancer.

With HDR brachytherapy, radiation is delivered directly to the cancer target through the use of catheters, needles or applicators inserted into a body cavity or directly into the tumor. A computer-controlled delivery system is used to optimize the dose distribution to the target. As a result of this precise delivery, the surrounding healthy tissue and critical organs are preferentially spared from high doses of radiation and side effects may be reduced.

Unlike low dose rate brachytherapy treatment, HDR therapy can be delivered on an outpatient basis at Cancer Centers of North Carolina's office, which incorporates all patient needs in one central location. In addition, treatment times for HDR brachytherapy are typically 10-15 minutes in duration instead of several days that are required for low dose rate brachytherapy. Cancer Centers of North Carolina is currently administering HDR primarily on breast and gynecologic cancers.

The HDR brachytherapy program at Cancer Centers of North Carolina is directed by its board-certified radiation oncologists, Dr. John Reilly and Dr. Kolby Sidhu. "HDR brachytherapy is a very effective addition to our fight against cancer. This technique delivers a high dose of radiation directly to the area of disease," according to Dr. Reilly. Dr. Sidhu adds, "Cancer patients benefit by having more treatment options. There is also the potential benefit for a shorter course of treatment, particularly for breast cancer patients being treated with Mammosite(R)."

About Cancer Centers of North Carolina

Cancer Centers of North Carolina (CCNC) has been providing comprehensive cancer care in the greater Triangle area for 30 years. Beginning as a single physician practice, originally named Raleigh Hematology Oncology, CCNC has grown to a physician staff of thirteen medical oncologists, two radiation oncologists, a head and neck surgical oncologist and a gynecologic oncologist, and offers services in Raleigh, North Raleigh, Cary, Clayton, and Dunn. The practice provides advanced state-of-the-art diagnostic and therapeutic services including administration of chemotherapy, biologic and targeted therapies, Computed Tomography (CT), Intensity Modulated Radiation Therapy (IMRT), laboratory and pharmacy services, and an extensive clinical trials program connecting patients to leading cancer investigators around the country. CCNC brings the best of medical science and cancer care support services together in one pleasant, convenient, community- based organization. For more information, visit www.cancercentersofnc.com

CCNC is united in healing with US Oncology, supporting the nation's foremost cancer treatment and research network to accelerate the availability and use of evidence-based medicine and shared best practices. With more than 1,227 physicians treating more than 650,000 patients at 468 locations in 39 states, the US Oncology network and CCNC provide cancer patients with access to the latest advancements in therapies, clinical research and technology, as well as best-in-class clinical and operational processes that help to advance the quality, safety and cost effectiveness of cancer care. For more information, visit www.usoncology.com.


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):